BioSpace News Archive

Learn all about the interview etiquette of successful job seekers, including how to prepare for an interview, how to dress, strike a conversation, and more.

HERA-CD40L Induces T-Cell-Mediated Anti-Tumor Immune Response through Activation of Antigen-Presenting Cells

With a new wave of migraine medications now on the market from multiple drugmakers that block the calcitonin gene-related peptide receptor (CGRP-R), Express Scripts has chosen to back two medications and exclude a third from the list of drugs it will carry.

San Mateo, Calif.-based startup CuraSen Therapeutics surged forward this morning with $54.5 million in Series A funding and a leadership team that includes executives from Afferent Pharmaceuticals, a company acquired by Merck in 2016 for $1.2 billion.

The U.S. FDA approved Pfizer’s PARP inhibitor, Talzenna (talazoparib), for patients with a germline BRCA-mutated (gBRCAm), HER2-negative breast cancer. The agency also approved Myriad Genetics’ diagnostic assay to identify the mutation.

Bone-on-bone knee pain from osteoarthritis can be agonizing and often results in surgery. But for some patients, there is another therapy option gaining ground – engineered cartilage implants.

Researchers at the University of Cambridge published research in the journal Nature Communications that suggests spontaneous DNA mutations may cause the majority of dementias.

How does big pharma expand pipeline opportunities? What are the latest developments in partnering trends with Chinese investors? What innovations are most promising in rare disease and orphan drug development? These and many more industry-relevant questions will be addressed at the 24th annual BIO-Europe®, a global life science partnering event starting on November 5.

The Minnesota Attorney General is calling out Sanofi-Aventis, Novo Nordisk and Eli Lilly over alleged price gouging for insulin. This week Minnesota Attorney General Lori Swanson filed a lawsuit against the three companies over insulin price hikes.

Eisai Co. and Purdue Pharma announced topline results from their SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.